Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.0
4.2
Journals
Biology
Special Issues
The Development and Therapeutic Intervention of Non-alcoholic Steatohepatitis (Nash)
share announcement

The Development and Therapeutic Intervention of Non-alcoholic Steatohepatitis (Nash)

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Medical Biology".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 4964

Special Issue Editors

Dr. Bin Qiu

E-Mail Website
Guest Editor
Department of Pharmacology, Yale University School of Medicine, Yale University, New Haven, CT 06520, USA
Interests: NAFLD; NASH; liver fibrosis; steatosis; obesity; adipocyte differentiation; autophagy; mitophagy; neointima formation; protein post-translational modification; MKP1; FKBP5
Dr. Yi Luan

E-Mail Website
Guest Editor
Department of Pharmacology, Yale University School of Medicine, Yale University, New Haven, CT 06520, USA
Interests: neutrophil; macrophage; myeloid cells; immune response; tumor immunity; mTOR signaling pathway; protein degradation

Special Issue Information

Dear Colleagues,

Non-alcoholic steatohepatitis (NASH) is a severe type of non-alcoholic fatty liver disease (NAFLD), accompanied by the presence of steatosis, hepatocellular injury, and ballooning. The NASH-induced recruitment of immune cells also contributes to liver inflammation and the activation of hepatic stellate cells (HSCs), leading to progressive liver fibrosis and ultimately to cirrhosis and hepatocellular carcinoma (HCC). There is currently no effective pharmacological therapy approved for NASH, and efforts to control complications arising from the condition are far from satisfactory. Therefore, understanding the underlying mechanisms that govern the development of NASH will play an important role in identifying new modalities for therapeutic intervention.

The goal of this Special Issue is to broaden our understanding of the development and therapy of NASH. We invite the submission of reviews, comments, and original research articles that cover, but are not restricted to, the following areas related to NASH:

-Steatosis and hepatic lipotoxicity;
-Hepatocyte apoptosis;
-Immune cells infiltration and inflammation;
-Hepatic stellate cell (HSC) activation;
-Liver fibrosis;
-Therapeutic intervention to treat NASH.

Dr. Bin Qiu
Dr. Yi Luan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-alcoholic steatohepatitis (NASH)
  • non-alcoholic fatty liver disease (NAFLD)
  • steatosis
  • lipotoxicity
  • hepatocellular apoptosis
  • inflammation
  • hepatic stellate cell (HSC) activation
  • liver fibrosis
  • therapeutic interventions

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 14096 KiB  
Article
Feasibility of Ultrasound Attenuation Imaging for Assessing Pediatric Hepatic Steatosis
by Kyungchul Song, Nak-Hoon Son, Dong Ryul Chang, Hyun Wook Chae and Hyun Joo Shin
Biology 2022, 11(7), 1087; https://doi.org/10.3390/biology11071087 - 20 Jul 2022
Cited by 4 | Viewed by 1731
Abstract
We investigated the feasibility of ultrasound attenuation imaging (ATI) for assessing pediatric hepatic steatosis. A total of 111 children and adolescents who underwent liver ultrasonography with ATI for suspected hepatic steatosis were included. Participants were classified into the normal, mild, or moderate–severe fatty [...] Read more.
We investigated the feasibility of ultrasound attenuation imaging (ATI) for assessing pediatric hepatic steatosis. A total of 111 children and adolescents who underwent liver ultrasonography with ATI for suspected hepatic steatosis were included. Participants were classified into the normal, mild, or moderate–severe fatty liver group according to grayscale US findings. Associations between clinical factors, magnetic resonance imaging proton density fat fraction, steatosis stage and ATI values were evaluated. To determine the cutoff values of ATI for staging hepatic steatosis, areas under the curve (AUCs) were analyzed. Factors that could cause measurement failure with ATI were assessed. Of 111 participants, 88 had successful measurement results. Median ATI values were significantly increased according to steatosis stage (p < 0.001). Body mass index (BMI) was a significant factor for increased ATI values (p = 0.047). To differentiate fatty liver from normal liver, a cutoff value of 0.59 dB/cm/MHz could be used with an AUC value of 0.853. To differentiate moderate to severe fatty liver from mild fatty liver, a cutoff value of 0.69 dB/cm/MHz could be used with an AUC value up to 0.91. ATI can be used in children as an effective ultrasonography technique for quantifying and staging pediatric hepatic steatosis. Full article
(This article belongs to the Special Issue The Development and Therapeutic Intervention of Non-alcoholic Steatohepatitis (Nash))
►▼ Show Figures

Figure 1

13 pages, 1868 KiB  
Article
Comparison of the Modified TyG Indices and Other Parameters to Predict Non-Alcoholic Fatty Liver Disease in Youth
by Kyungchul Song, Hae Won Lee, Han Saem Choi, Goeun Park, Hye Sun Lee, Su Jin Kim, Myeongseob Lee, Junghwan Suh, Ahreum Kwon, Ho-Seong Kim and Hyun Wook Chae
Biology 2022, 11(5), 685; https://doi.org/10.3390/biology11050685 - 29 Apr 2022
Cited by 8 | Viewed by 2295
Abstract
We investigated the modified triglycerides-glucose (TyG) indices and other markers for non-alcoholic fatty liver disease (NAFLD) in 225 participants aged 10–19 years, and the participants were divided into subgroups according to their NAFLD grade. We performed logistic regression analysis and calculated the odds [...] Read more.
We investigated the modified triglycerides-glucose (TyG) indices and other markers for non-alcoholic fatty liver disease (NAFLD) in 225 participants aged 10–19 years, and the participants were divided into subgroups according to their NAFLD grade. We performed logistic regression analysis and calculated the odds ratios (ORs) with 95% confidence intervals (CIs) of tertiles 2 and 3 for each parameter, with those of tertile 1 as a reference. The area under the receiver operating characteristic (ROC) curve was calculated to compare the parameters for identifying NAFLD. TyG and modified indices, aspartate transaminase-to-platelet ratio index (APRI)-body mass index (BMI), APRI-BMI standard deviation score (SDS), APRI waist-to-hip ratio, fibrosis-4 index (FIB)-4, and hepatic steatosis index (HSI) were higher in participants with NAFLD than in those without NAFLD. The ORs and 95% CIs for NAFLD progressively increased across tertiles of each parameter. TyG and modified TyG indices, FIB-4, HSI, and modified APRIs, except APRI waist-to-height ratio, predicted NAFLD significantly through ROC curves. Modified TyG indices, APRI-BMI SDS, and HSI were superior to the other markers for NAFLD prediction. Modified TyG indices, APRI-BMI SDS, and HSI appear to be useful for assessing NAFLD in youths. Full article
(This article belongs to the Special Issue The Development and Therapeutic Intervention of Non-alcoholic Steatohepatitis (Nash))
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop